Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesvTv Therapeutics Inc

vTv Therapeutics Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
21.47 USD 0.47 ( 2.24%)
Last update at 2026-11-11T21:00:00Z
VOLUME
11338
Market Cap
68.61M

Momentum Score

…

vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 inhibitor, which is in Phase III trial for the treatment of psoriasis, COPD, and atopic dermatitis, as well as TTP-RA, a RAGE antagonist for type 1 diabetes prevention. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2"related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress; and Azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for glioblastoma, other cancers, and cancer treatment-related conditions. vTv Therapeutics Inc. has license agreements with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593 for therapeutic, prophylactic, and diagnostic application; and Anteris Bio, Inc. to develop and commercialize HPP971, a Nrf2 activator, as well as with Cantex Pharmaceuticals, Inc.; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
21.04
Low
21.71
High
52 Week Price Range
7.38
Low
39.60
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Public information on vTv Therapeutics is limited; historically it operated as a small clinical-stage biotechnology company focused on therapies for metabolic and central nervous system disorders. Long-term growth drivers depend on clinical progress of any remaining pipeline programs, successful licensing or partnership transactions, and access to capital to advance development. Investors may find potential upside if programs show clinical efficacy or attract partners, but available information is sparse and progress has been uneven.
Key risks include clinical and regulatory failure, limited public disclosure and liquidity, and significant financing and dilution risk.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
21.00
Dividend Yield
-
Revenue TTM
0.01M
Revenue Per Share
0.00
Gross Profit TTM
-9.93M
Debt / Equity
-0.02
ROE
-4978.30%
Net Debt
-8.92M
ROCE
-5649.12%
Diluted EPS TTM
-8.72

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -24.87M -17.62M -12.80M -21.84M -23.64M
Minority interest -5.91M 4.74M -4.30M 40.18M 62.48M
Net income -25.07M -17.73M -8.83M -21.94M -7.91M
Selling general administrative 12.20M 12.34M 7.25M 8.54M 9.22M
Gross profit 2.02M 4.00M 6.41M 2.76M 12.43M
Reconciled depreciation 0.09M 0.09M 0.09M 0.04M 0.22M
Ebit -22.54M -21.66M -11.85M -20.89M -20.57M
Ebitda -24.86M -17.60M -12.11M -20.01M -20.36M
Depreciation and amortization -2.32M 4.06M -0.26M 0.88M 0.22M
Non operating income net other -3.26M - 0.01M 0.05M -
Operating income -22.54M -21.66M -11.85M -20.89M -19.82M
Other operating expenses 24.56M 25.67M 18.27M 23.66M 32.26M
Interest expense 0.01M 0.01M 0.69M 1.83M 3.29M
Tax provision 0.20M 0.12M 0.00M 0.10M 0.20M
Interest income 0.35M 0.00M 0.01M 0.05M 0.06M
Net interest income 0.34M -0.01M -0.68M -1.77M -3.23M
Income tax expense 0.20M 0.12M -3.98M 0.10M 0.20M
Total revenue 2.02M 4.00M 6.41M 2.76M 12.43M
Total operating expenses 24.56M 25.67M 18.27M 23.66M 32.26M
Cost of revenue - - - 15.12M 23.04M
Total other income expense net -2.33M 4.05M -0.95M -0.95M -0.59M
Net income from continuing ops -25.07M -17.73M -12.80M -21.94M -23.84M
Net income applicable to common shares -19.16M -12.99M -8.50M -17.91M -8.65M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 11.02M 33.24M 25.47M 14.79M 9.27M
Other current assets 1.11M 2.54M 2.05M 0.94M 0.81M
Total liab 29.57M 43.98M 35.21M 94.89M 58.29M
Total stockholder equity -24.68M -10.74M -9.74M -80.10M -49.02M
Other current liab 6.17M 4.85M 8.06M 4.20M 4.84M
Common stock 0.03M 1.05M 0.90M 0.77M 0.64M
Capital stock 0.03M 1.05M 0.90M 0.77M 0.64M
Retained earnings -281.04M -265.52M -248.83M -290.04M -233.52M
Other liab - 19.35M 1.26M 3.93M 3.89M
Other assets - - - 7.21M 2.94M
Cash 9.45M 12.13M 13.41M 5.75M 1.78M
Total current liabilities 10.62M 7.71M 8.50M 6.39M 13.38M
Current deferred revenue 0.02M 0.02M 0.04M 0.03M 0.03M
Net debt -8.92M -11.41M -12.48M -4.83M 5.34M
Short term debt 0.36M 0.38M 0.44M 0.24M 6.28M
Short long term debt 0.19M 0.22M 0.26M 0.08M 6.17M
Short long term debt total 0.53M 0.72M 0.93M 0.92M 7.11M
Other stockholder equity 256.33M 253.74M 238.19M 209.16M 183.86M
Property plant equipment - 0.21M 0.68M 0.37M 1.00M
Total current assets 10.66M 27.09M 15.62M 7.21M 2.84M
Long term investments 0.00M 5.59M 9.17M 6.72M 2.48M
Net tangible assets - 5.84M -9.74M 3.79M -49.02M
Short term investments 0.07M - - 6.72M 0.25M
Net receivables 0.10M 12.42M 0.06M 0.16M 0.01M
Inventory - 0.01M 0.10M 0.37M 0.25M
Accounts payable 4.08M 2.46M 8.02M 6.12M 7.07M
Accumulated other comprehensive income - - - - -0.15M
Common stock total equity - 1.05M - 0.54M 0.64M
Retained earnings total equity - -265.52M - -290.04M -233.52M
Non currrent assets other - 0.35M - -6.72M 2.94M
Non current assets total 0.36M 6.14M 9.85M 7.57M 6.43M
Capital lease obligations 0.34M 0.49M 0.68M 0.83M 0.94M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.02M 0.00M 0.00M 0.24M 0.01M
Change to liabilities -0.86M 0.82M -1.21M -0.62M -6.23M
Total cashflows from investing activities -0.02M -0.02M -0.02M 0.24M 0.01M
Net borrowings -0.03M 0.17M -4.96M -10.07M -4.89M
Total cash from financing activities 14.75M 26.98M 19.47M 22.87M 16.61M
Change to operating activities -0.40M -0.89M -1.53M 0.32M 1.09M
Net income -25.07M -17.73M -12.80M -21.94M -23.84M
Change in cash -1.29M 7.67M 1.47M 0.09M -10.24M
Begin period cash flow 13.41M 5.75M 4.28M 4.18M 14.42M
End period cash flow 12.13M 13.41M 5.75M 4.28M 4.18M
Total cash from operating activities -16.02M -19.31M -18.00M -23.02M -26.86M
Issuance of capital stock 5.04M 26.76M 24.43M 32.94M 21.50M
Depreciation 0.09M 0.09M 0.09M 0.04M 0.22M
Other cashflows from investing activities - - - 0.31M 0.01M
Dividends paid - - - 0.99M -
Change to inventory - -0.89M -1.98M 0.62M -
Change to account receivables -0.12M 0.10M -0.15M -0.01M 8.00M
Sale purchase of stock 9.75M - 14.43M 0.99M 21.50M
Other cashflows from financing activities 10.52M 0.93M 0.50M 0.50M 0.50M
Change to netincome 4.50M -6.45M 1.01M 1.23M 2.66M
Capital expenditures 0.02M 0.02M 0.02M 0.07M 0.01M
Change receivables -0.12M - -0.15M -0.01M 8.00M
Cash flows other operating 5.43M - -5.32M -2.26M -8.68M
Cash and cash equivalents changes -1.29M - 1.47M 0.09M -10.24M
Change in working capital 5.38M 0.04M -2.71M -2.05M -7.54M
Stock based compensation 1.27M 2.36M 1.01M 1.52M 2.68M
Other non cash items 2.30M -4.06M 0.38M 0.53M 1.01M
Free cash flow -16.04M -19.31M -18.00M -23.09M -26.86M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
VTVT
vTv Therapeutics Inc		 0.47
2.24%		 21.47 - - 3631.36 - 3515.11 -1.96
NVO
Novo Nordisk A/S		 0.41
1.00%		 41.10 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -0.86
0.16%		 547.03 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 43.35
4.73%		 959.41 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

vTv Therapeutics Inc

vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 inhibitor, which is in Phase III trial for the treatment of psoriasis, COPD, and atopic dermatitis, as well as TTP-RA, a RAGE antagonist for type 1 diabetes prevention. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2"related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress; and Azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for glioblastoma, other cancers, and cancer treatment-related conditions. vTv Therapeutics Inc. has license agreements with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593 for therapeutic, prophylactic, and diagnostic application; and Anteris Bio, Inc. to develop and commercialize HPP971, a Nrf2 activator, as well as with Cantex Pharmaceuticals, Inc.; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.

3980 Premier Drive, High Point, NC, United States, 27265

336 841 0300

https://vtvtherapeutics.com

16

Name Title Year Born
Mr. Paul J. Sekhri M.Sc., MSc CEO, Pres & Director 1958
Mr. Barry Brown Chief Accounting Officer 1961
Dr. Carmen Valcarce Ph.D. Chief Scientific Officer & Exec. VP NA
Vanessa McDade Chief Admin. Officer NA
Mr. David M. Lambert III Sr. VP & Gen. Counsel NA
Mr. Richard S. Nelson Exec. VP of Corp. Devel. & Director 1970
Mr. Paul J. Sekhri M.Sc. CEO, President & Director 1958
Mr. Steven Tuch M.B.A. Executive VP & CFO 1969
Mr. Richard S. Nelson Executive VP of Corporate Development & Director 1971
Dr. Carmen Valcarce Ph.D. Chief Scientific Officer & Executive VP NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…